Fate Therapeutics to Present at Upcoming Investor Conferences
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on developing iPSC-derived off-the-shelf cellular immunotherapies, has announced its participation in two major investor conferences in September 2025.
The company will attend the 2025 Wells Fargo Healthcare Conference on September 3 in Boston for one-on-one meetings, and will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on September 4 at 10:55 AM ET in New York. Webcasts of the presentations, if recorded, will be available on the company's investor relations website.
Fate Therapeutics (NASDAQ: FATE), azienda biofarmaceutica in fase clinica specializzata nello sviluppo di immunoterapie cellulari allogeniche derivate da iPSC pronte all'uso, ha annunciato la sua partecipazione a due importanti conferenze per investitori a settembre 2025.
L'azienda sar脿 presente al 2025 Wells Fargo Healthcare Conference il 3 settembre a Boston per incontri one-to-one e parteciper脿 a un fireside chat al Cantor Global Healthcare Conference 2025 il 4 settembre alle 10:55 ET a New York. Se disponibili, le webcast delle presentazioni saranno pubblicate sul sito dedicato agli investitori della societ脿.
Fate Therapeutics (NASDAQ: FATE), una compa帽铆a biofarmac茅utica en fase cl铆nica centrada en desarrollar inmunoterapias celulares off-the-shelf derivadas de iPSC, ha anunciado su participaci贸n en dos importantes conferencias para inversores en septiembre de 2025.
La compa帽铆a asistir谩 al 2025 Wells Fargo Healthcare Conference el 3 de septiembre en Boston para reuniones one-on-one, y participar谩 en un fireside chat en el Cantor Global Healthcare Conference 2025 el 4 de septiembre a las 10:55 AM ET en Nueva York. Las retransmisiones por web de las presentaciones, si est谩n disponibles, se publicar谩n en la web de relaciones con inversores de la compa帽铆a.
Fate Therapeutics (NASDAQ: FATE)電� iPSC 鞙犽灅鞚� 旮办劚頀�(off-the-shelf) 靹疙彫 氅挫棴旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎巾殞靷, 2025雲� 9鞗旍棎 鞐措Μ電� 霊� 瓯挫潣 欤检殧 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
須岇偓電� 9鞗� 3鞚� 氤挫姢韯挫棎靹� 鞐措Μ電� 2025 Wells Fargo Healthcare Conference鞐� 1:1 氙疙寘鞚� 鞙勴暣 彀胳劃頃橂┌, 9鞗� 4鞚� 鞓れ爠 10鞁� 55攵�(霃欕秬鞁滉皠)鞐� 雺挫殨鞐愳劀 鞐措Μ電� Cantor Global Healthcare Conference 2025鞚� fireside chat鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 氚滍憸鞚� 鞗轨簮鞀ろ姼臧� 鞝滉车霅橂姅 瓴届毎 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
Fate Therapeutics (NASDAQ: FATE), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans le d茅veloppement d'immunoth茅rapies cellulaires 芦 off-the-shelf 禄 d茅riv茅es d'iPSC, a annonc茅 sa participation 脿 deux grandes conf茅rences investisseurs en septembre 2025.
La soci茅t茅 assistera au 2025 Wells Fargo Healthcare Conference le 3 septembre 脿 Boston pour des r茅unions individuelles et participera 脿 un fireside chat lors du Cantor Global Healthcare Conference 2025 le 4 septembre 脿 10h55 ET 脿 New York. Les webcasts des pr茅sentations, si disponibles, seront publi茅s sur le site relations investisseurs de la soci茅t茅.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von iPSC-abgeleiteten, sofort verf眉gbaren (off-the-shelf) zellul盲ren Immuntherapien konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im September 2025 angek眉ndigt.
Das Unternehmen wird am 2025 Wells Fargo Healthcare Conference am 3. September in Boston f眉r One-on-One-Gespr盲che teilnehmen und am Cantor Global Healthcare Conference 2025 am 4. September um 10:55 Uhr ET in New York in einem Fireside Chat vertreten sein. Webcasts der Pr盲sentationen werden, sofern verf眉gbar, auf der Investor-Relations-Website des Unternehmens bereitgestellt.
- None.
- None.
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, announced that the Company will participate in the following upcoming investor conferences:
- 2025 Wells Fargo Healthcare Conference, including one-on-one meetings on Wednesday, September 3, 2025 in Boston, Massachusetts
- Cantor Global Healthcare Conference 2025, including a fireside chat at 10:55 AM ET on Thursday, September 4, 2025 in New York, New York
A live webcast, if recorded, of each presentation can be accessed under 鈥淓vents & Presentations鈥� in the Investors section of the Company鈥檚 website at . The archived webcast will be available on the Company鈥檚 website shortly after the event.
About聽Fate Therapeutics, Inc.
Fate Therapeutics聽is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company鈥檚 pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients.聽Fate Therapeutics聽is headquartered in聽San Diego, CA.聽For more information, please visit聽.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
FAQ
When is Fate Therapeutics (FATE) presenting at the Wells Fargo Healthcare Conference 2025?
What time is Fate Therapeutics' presentation at the Cantor Global Healthcare Conference 2025?
Where can I watch Fate Therapeutics' (FATE) investor conference presentations?
What type of company is Fate Therapeutics (FATE)?
